UK biotech Compass Pathways revealed this morning that they reached the primary endpoint in a Phase IIb clinical trial of psilocybin therapy.
Category Press Release
Country United Kingdom
Companies Featured
COMPASS PathwaysCOMPASS Pathways is a publicly listed company (NASDAQ) that is developing psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. COMPASS is one of the largest psychedelic companies and has received substantial investment from atai.